The Medical Letter on Drugs and Therapeutics
FROM
ISSUE 1572
ISSUE 1572
May 20, 2019
Omadacycline (Nuzyra) - A New Tetracycline Antibiotic
| Subscribers: Log in to read full article. Not a subscriber? Subscribe or purchase article. |
May 20, 2019 (Issue: 1572)
The FDA has approved omadacycline (Nuzyra – Paratek),
a semisynthetic tetracycline derivative, for once-daily
IV and oral treatment of community-acquired bacterial
pneumonia (CAP) and acute bacterial skin and skin
structure infections (ABSSSIs) in adults.
... more
The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.
Would you like to read the rest of this article? Gain access below.
Subscribe
Subscriptions to The Medical Letter on Drugs and Therapeutics include:
- Print version published and mailed biweekly (26 issues/year)
- Unlimited online access to current and past issues (1988 - present)
- Mobile App for iOS, Android, and Kindle Fire
- FREE online per issue CME/CE
Purchase this article:
Title: Omadacycline (Nuzyra) - A New Tetracycline Antibiotic
Article code: 1572b
Electronic, downloadable article - $45
Article code: 1572b
Electronic, downloadable article - $45
Gain access through your organization
Ask your librarian to consider an Institutional Subscription to The Medical Letter.
Recommend to your librarian
